CDKN2A-positive breast cancers in young women from Poland

Breast Cancer Research and Treatment

Volumn 103, Issue 3, 2007, Pages 355-359

  Dȩbniak, Tadeusz ^a   Cybulski, Cezary ^a   Górski, Bohdan ^a   Huzarski, Tomasz ^a   Byrski, Tomasz ^a   Gronwald, Jacek ^a   Jakubowska, Anna ^a   Kowalska, Elzbieta ^a   Oszurek, Oleg ^a   Narod, Steven A ^b   Lubiński, Jan ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Centre for Research on Women's Health   (Canada)

Author keywords

Breast cancer; CDKN2A gene; Germline mutations; Tumor characteristics

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ESTROGEN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST TUMOR; CONFIDENCE INTERVAL; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOMICS; HUMAN; HUMAN TISSUE; PATHOLOGY; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL ANALYSIS;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; FEMALE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; MUTATION; POLAND; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, ESTROGEN; VARIATION (GENETICS);

EID: 34250641990     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9382-x     Document Type: Article

References (23)

1. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707
2. Van Zee KJ, Calvano JE, Bisogna M (1998) Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 16:2723-2727
3. Nielsen NH, Roos G, Emdin SO et al (2001) Methylation of the p16(Ink4a) tumor suppressor gene 5′-CpG island in breast cancer. Cancer Lett 163:59-69
4. Gorgoulis VG, Koutroumbi EN, Kotsinas A et al (1998) Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med 4:807-822
5. Borg A, Sandberg T, Nilsson K et al (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92:1260-1266
6. Dȩbniak T, Górski B, Huzarski T et al (2005) Common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 42:763-765
7. Lubiński J, Górski B, Huzarski T et al (2006) BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 99:71-76
8. Dȩbniak T, Górski B, Scott RJ et al (2004) Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer. Int J Cancer 110:558-562
9. Ranade K, Hussussian CJ, Sikorski RS et al (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114-116
10. Lilischkis R, Sarcevic B, Kennedy C et al (1996) Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 66:249-254
11. Mantelli M, Barile M, Ciotti P et al (2002) High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 107:214-221
12. Harland M, Holland EA, Ghiorzo P et al (2000) Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 28:45-57
13. Dȩbniak T, Scott RJ, Huzarski T et al (2005) The CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 65:835-839
14. Dȩbniak T, Scott RJ, Huzarski T et al (2006) CDKN2A common variant and multi-organ cancer risk-a population-based study. Int J Cancer 118:3180-3182
15. Bertram CG, Gaut RM, Barrett JH et al (2002) An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 119:961-965
16. Spica T, Portela M, Gerard B et al (2006) The A148T variant of CDKN2A gene is not associated with melanoma risk in the French and Italian populations. J Invest Dermatol 126:1658-1660
17. Honrado E, Benitez J, Palacios J (2006) Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol 59:27-39
18. Sun CC, Lenoir G, Lynch H et al (1996) In-situ breast cancer and BRCA1. Lancet 348:408
19. Lakhani SR (1999) The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1:31-35
20. Tischkowitz MD, Foulkes WD (2006) The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle 5:963-967
21. Foulkes WD, Stefansson IM, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485
22. Huzarski T, Lener M, Domagala W et al (2005) The 3020insC allele of NOD2 predisposes to early-onset breast cancer. Breast Cancer Res Treat 89:91-93
23. Cybulski C, Górski B, Huzarski T et al (2006) CHEK2-positive breast cancers in young women from Poland. Clin Cancer Res 12:4832-4835